Abstract 14638: Survival Outcomes in Hospitalized COVID19 Patients With New Onset Cardiomyopathy

Abstract

Introduction: Cardiac injury is known to occur in patients with COVID19 infection and is associated with a poor prognosis. However, there is limited data assessing the survival outcomes in hospitalized COVID19 patients with new-onset cardiomyopathy (NOC). We studied the impact of NOC on short and long term mortality in hospitalized COVID19 patients. Methods: We reviewed all cases of hospitalized COVID19 patients from the Cleveland Clinic COVID19 registry from 18 th March, 2020 to 18 th May, 2021 who received an in-hospital echocardiogram and had any prior echocardiogram to compare. The mean interval between the in-hospital and prior echocardiogram was 2.8 years. NOC was defined as a reduction in left ventricular ejection fraction (LVEF) of > 10% with a new LVEF of < 53%. The 30-day and 1-year mortality of patients with NOC were analyzed. Results: Of the 1537 hospitalized COVID19 patients receiving echocardiogram, 907 with a prior echocardiogram were included, of which 77 (8.5%) had NOC. Out of the 907 patients, 229 (25.2%) died within 30-days and 519 (57.2%) died within one year. It was found that patients with NOC had higher 30-day mortality than those without NOC (24.2% vs 36.4%, p=0.0078). However, the 1-year mortality was similar in the two groups (41.4% vs 45.3%, p=0.21). Conclusions: We found that NOC in hospitalized COVID19 patients was associated with higher 30-day mortality, however, it did not adversely impact the 1-year survival. Our findings suggest that although NOC is associated with worse short-term outcomes, long-term survival was primarily driven by the underlying disease process rather than the NOC.